Morgan Stanley analyst Sean Laaman raised the firm’s price target on Axsome Therapeutics (AXSM) to $194 from $191 and keeps an Overweight rating on the shares ahead of the company’s Q3 earnings report due on November 3. The firm expects the focus to be on updates regarding the sNDA filing for AXS-05 in ADA, Auvelity commercial progress in MDD, and early commercial dynamics for Symbravo in migraine, the analyst tells investors in a preview.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics: Strategic Growth and Promising Commercial Progress Drive Buy Rating
- Axsome Therapeutics recognizes Mental Illness Awareness Week
- Axsome Therapeutics initiated with a Buy at B. Riley
- Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
- RBC lists biotech winners should RFK depart HHS